Cargando…

Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD

In a multinational placebo‐controlled phase III clinical trial in 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, treatment with the Nrf2 activator bardoxolone methyl increased estimated glomerular filtration rate, a measure of kidney function, but also resulted in i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewis, James H., Jadoul, Michel, Block, Geoffrey A., Chin, Melanie P., Ferguson, Deborah A., Goldsberry, Angie, Meyer, Colin J., O’Grady, Megan, Pergola, Pablo E., Reisman, Scott A., Wigley, W. Christian, Chertow, Glenn M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877861/ https://www.ncbi.nlm.nih.gov/pubmed/32860734 http://dx.doi.org/10.1111/cts.12868

Ejemplares similares

Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function
por: Nagasu, Hajime, et al.
Publicado: (2019)

Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers
por: Reisman, Scott A., et al.
Publicado: (2015)

Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
por: Rojas-Rivera, Jorge, et al.
Publicado: (2012)

Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease
por: Chertow, Glenn M., et al.
Publicado: (2017)

Bardoxolone methyl: drug development for diabetic kidney disease
por: Kanda, Hironori, et al.
Publicado: (2020)

Bardoxolone conjugation enables targeted protein degradation of BRD4
por: Tong, Bingqi, et al.
Publicado: (2020)

Renoprotection and the Bardoxolone Methyl Story – Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents
por: Onuigbo, Macaulay
Publicado: (2013)

Anticholestatic Effect of Bardoxolone Methyl on Hepatic Ischemia-reperfusion Injury in Rats
por: Kim, Joohyun, et al.
Publicado: (2020)

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease
por: Sun, Qi, et al.
Publicado: (2021)

Emerging Role of Clinical Genetics in CKD
por: Devarajan, Prasad, et al.
Publicado: (2022)

Hemoglobin response to ferric citrate in patients with nondialysis‐dependent chronic kidney disease and iron deficiency anemia
por: Pergola, Pablo E., et al.
Publicado: (2018)

The potential roles of galectin-3 in AKI and CKD
por: Wang, Fengyun, et al.
Publicado: (2023)

Understanding the role of the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2—lessons from evolution, the animal kingdom and rare progeroid syndromes
por: Stenvinkel, Peter, et al.
Publicado: (2019)

Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses
por: Block, Geoffrey A, et al.
Publicado: (2019)

Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)
por: Lynch, David R., et al.
Publicado: (2020)

Bardoxolone Methyl Prevents Mesenteric Fat Deposition and Inflammation in High-Fat Diet Mice
por: Dinh, Chi H. L., et al.
Publicado: (2015)

Bardoxolone methyl ameliorates osteoarthritis by inhibiting osteoclastogenesis and protecting the extracellular matrix against degradation
por: Yang, Ruijia, et al.
Publicado: (2023)

Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties
por: Wang, Yan-Yang, et al.
Publicado: (2014)

Bardoxolone methyl inhibits the infection of rabies virus via Nrf2 pathway activation in vitro
por: Chi, Ying Lin, et al.
Publicado: (2023)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)
por: Nangaku, Masaomi, et al.
Publicado: (2020)

In vitro study on effect of bardoxolone methyl on cisplatin-induced cellular senescence in human proximal tubular cells
por: Kurosaki, Yoshifumi, et al.
Publicado: (2022)

Cardiac and renal function in patients with type 2 diabetes who have chronic kidney disease: potential effects of bardoxolone methyl
por: McCullough, Peter A, et al.
Publicado: (2012)

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD
por: Balk, Ethan M., et al.
Publicado: (2022)

Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells
por: Wang, Yan-Yang, et al.
Publicado: (2015)

Bardoxolone-Methyl Prevents Oxidative Stress-Mediated Apoptosis and Extracellular Matrix Degradation in vitro and Alleviates Osteoarthritis in vivo
por: Pang, Zhiying, et al.
Publicado: (2021)

Repeated glucose spikes and insulin resistance synergistically deteriorate endothelial function and bardoxolone methyl ameliorates endothelial dysfunction
por: Ogiso, Kazuma, et al.
Publicado: (2022)

Bardoxolone-Methyl (CDDO-Me) Impairs Tumor Growth and Induces Radiosensitization of Oral Squamous Cell Carcinoma Cells
por: Hermann, Cornelius, et al.
Publicado: (2021)

Bardoxolone Methyl Ameliorates Myocardial Ischemia/Reperfusion Injury by Activating the Nrf2/HO-1 Signaling Pathway
por: Huang, Anwu, et al.
Publicado: (2023)

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism
por: Block, Geoffrey A., et al.
Publicado: (2019)

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy
por: Chien, Jia-Ying, et al.
Publicado: (2021)

Bardoxolone Methyl Ameliorates Compression-Induced Oxidative Stress Damage of Nucleus Pulposus Cells and Intervertebral Disc Degeneration Ex Vivo
por: Tian, Yueyang, et al.
Publicado: (2022)

46 Bardoxolone-methyl Microparticles Ameliorate Immune Dysfunction Following Burn and Inhalation Injury Through the NRF2/KEAP1 Axis
por: Seim, Roland F, et al.
Publicado: (2022)

Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis
por: McEwan, Phil, et al.
Publicado: (2022)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

Bardoxolone Methyl Prevents Fat Deposition and Inflammation in Brown Adipose Tissue and Enhances Sympathetic Activity in Mice Fed a High-Fat Diet
por: Dinh, Chi H. L., et al.
Publicado: (2015)

Bardoxolone Methyl Displays Detrimental Effects on Endothelial Bioenergetics, Suppresses Endothelial ET-1 Release, and Increases Endothelial Permeability in Human Microvascular Endothelium
por: Szczesny-Malysiak, Ewa, et al.
Publicado: (2020)

A cross-sectional study of the relationship between depression status, health care coverage, and sexual orientation
por: Liu, Yang, et al.
Publicado: (2023)

Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO(2)TECT Randomized Clinical Trial of ESA-Treated Patients
por: Parfrey, Patrick S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oj0ibfd8f4d873ijg76o74d64o